Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy

2021 ◽  
Author(s):  
Fumi Nakamura ◽  
Honoka Arai ◽  
Yasuhito Nannya ◽  
Motoshi Ichikawa ◽  
Shiho Furuichi ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Philadelphia Chromosome ◽  
Molecular Response ◽  
Major Molecular Response ◽  
Tyrosine Kinase Inhibitor Therapy ◽  
Acute Myeloid

Tyrosine kinase inhibitor therapy for acute myeloid leukemia with late-appearing Philadelphia chromosome

2012 ◽  
Vol 36 (1) ◽  
pp. e41-e42 ◽  
Author(s):  
Jun Aoki ◽  
Kazuhiko Kakihana ◽  
Takeshi Kobayashi ◽  
Yuka Hirashima ◽  
Hideki Akiyama ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Philadelphia Chromosome ◽  
Inhibitor Therapy ◽  
Tyrosine Kinase Inhibitor Therapy ◽  
Acute Myeloid

scholarly journals Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

Leukemia ◽  
2019 ◽  
Vol 33 (8) ◽  
pp. 2116-2120 ◽  
Author(s):  
L. Janssen ◽  
S. J. C. M. Frambach ◽  
N. A. E. Allard ◽  
M. T. E. Hopman ◽  
T. J. J. Schirris ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Tyrosine Kinase Inhibitor Therapy ◽  
Muscle Toxicity
Sign in / Sign up

Export Citation Format

Share Document